Stefan Suciu
Impact in
- Hematology top 0.1%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Oncology top 0.1%
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
- Hematology 126
- Acute Myeloid Leukemia Research 113
- Hematopoietic Stem Cell Transplantation 33
- Chronic Myeloid Leukemia Treatments 27
-
- Acute Lymphoblastic Leukemia research 104
- Co-authors
- Alexander M.M. Eggermont (38 shared papers)Gabriel Solbu (45 shared papers)Ulrich Keilholz (19 shared papers)Wim H.J. Kruit (16 shared papers)R Zittoun (30 shared papers)Alessandro Testori (20 shared papers)Cornelis J.A. Punt (14 shared papers)Martin Eric Gore (7 shared papers)
- Journals
- Blood (45 papers)European Journal of Cancer (29 papers)Journal of Clinical Oncology (28 papers)Annals of Hematology (15 papers)Leukemia (14 papers)
- Partner nations
- BelgiumFranceNetherlands
In The Last Decade
Stefan Suciu
290 papers receiving 17.7k citations
Stefan Suciu's Hit Papers
Peers
Comparison fields: 5 of 131
- Hematology 5.1k
- Oncology 9.0k
- Immunology 3.5k
- Genetics 1.1k
- Public Health, Environmental and Occupational Health 2.8k
Countries citing papers authored by Stefan Suciu
This map shows the geographic impact of Stefan Suciu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Suciu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Suciu more than expected).
Fields of papers citing papers by Stefan Suciu
This network shows the impact of papers produced by Stefan Suciu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Suciu. The network helps show where Stefan Suciu may publish in the future.
Co-authors
The 25 scholars most cited alongside Stefan Suciu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 300 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma Hit paper breakdown → | 2018 | 1503 |
| 2 | Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy Hit paper breakdown → | 2016 | 1099 |
| 3 | Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2015 | 1016 |
| 4 | 2008 | 505 | |
| 5 | Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group Hit paper breakdown → | 2011 | 474 |
| 6 | Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials | 1998 | 414 |
| 7 | 2020 | 354 | |
| 8 | 1989 | 335 | |
| 9 | 2013 | 327 | |
| 10 | 2016 | 308 | |
| 11 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Hit paper breakdown → | 2021 | 296 |
| 12 | 2003 | 289 | |
| 13 | 1992 | 284 | |
| 14 | 2003 | 276 | |
| 15 | 2005 | 257 | |
| 16 | 1998 | 247 | |
| 17 | Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial Hit paper breakdown → | 2020 | 237 |
| 18 | 2012 | 229 | |
| 19 | Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study Hit paper breakdown → | 2019 | 217 |
| 20 | 1998 | 202 |
About Stefan Suciu
Stefan Suciu is a scholar working on Hematology, Public Health, Environmental and Occupational Health, Oncology, Genetics and Pediatrics, Perinatology and Child Health, having authored 300 papers that have together received 18.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (113 papers), Acute Lymphoblastic Leukemia research (104 papers), Cutaneous Melanoma Detection and Management (42 papers), Childhood Cancer Survivors' Quality of Life (38 papers), Hematopoietic Stem Cell Transplantation (33 papers), Chronic Myeloid Leukemia Treatments (27 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Cancer Immunotherapy and Biomarkers (17 papers). The work is most often cited by research in Hematology (5.1k citations), Oncology (9.0k citations), Immunology (3.5k citations), Genetics (1.1k citations) and Public Health, Environmental and Occupational Health (2.8k citations). Stefan Suciu has collaborated with scholars based in Belgium, France and Netherlands. Frequent co-authors include Alexander M.M. Eggermont, Gabriel Solbu, Ulrich Keilholz, Wim H.J. Kruit, R Zittoun, Alessandro Testori, Cornelis J.A. Punt, Martin Eric Gore, Alan Spatz and François Salès. Their work appears in journals such as Blood, European Journal of Cancer, Journal of Clinical Oncology, Annals of Hematology and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.